The purpose of this study is to test a strategy to potentiate functional recovery of lower
limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug,
Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity
(STDP) stimulation and STDP stimulation with limb training.
Phase:
Early Phase 1
Details
Lead Sponsor:
Shirley Ryan AbilityLab
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)